HUE055678T2 - PPAR agonista vegyületek kristályos és só alakjai - Google Patents
PPAR agonista vegyületek kristályos és só alakjaiInfo
- Publication number
- HUE055678T2 HUE055678T2 HUE17787774A HUE17787774A HUE055678T2 HU E055678 T2 HUE055678 T2 HU E055678T2 HU E17787774 A HUE17787774 A HU E17787774A HU E17787774 A HUE17787774 A HU E17787774A HU E055678 T2 HUE055678 T2 HU E055678T2
- Authority
- HU
- Hungary
- Prior art keywords
- crystalline
- salt forms
- agonist compounds
- ppar agonist
- ppar
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404474P | 2016-10-05 | 2016-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE055678T2 true HUE055678T2 (hu) | 2021-12-28 |
Family
ID=60153508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE17787774A HUE055678T2 (hu) | 2016-10-05 | 2017-10-05 | PPAR agonista vegyületek kristályos és só alakjai |
Country Status (31)
Country | Link |
---|---|
US (3) | US10927094B2 (hu) |
EP (1) | EP3523283B1 (hu) |
JP (1) | JP7017563B2 (hu) |
KR (1) | KR20190057129A (hu) |
CN (1) | CN109843857B (hu) |
AU (1) | AU2017340763B2 (hu) |
BR (1) | BR112019006030A2 (hu) |
CA (1) | CA3036587A1 (hu) |
CO (1) | CO2019003162A2 (hu) |
CY (1) | CY1124655T1 (hu) |
DK (1) | DK3523283T3 (hu) |
ES (1) | ES2887008T3 (hu) |
HR (1) | HRP20211341T1 (hu) |
HU (1) | HUE055678T2 (hu) |
IL (1) | IL265730B (hu) |
JO (1) | JOP20190039B1 (hu) |
LT (1) | LT3523283T (hu) |
MA (1) | MA46460A (hu) |
MX (1) | MX2019003945A (hu) |
MY (1) | MY202008A (hu) |
PH (1) | PH12019500727A1 (hu) |
PL (1) | PL3523283T3 (hu) |
PT (1) | PT3523283T (hu) |
RS (1) | RS62245B1 (hu) |
RU (1) | RU2759724C2 (hu) |
SG (1) | SG11201901995TA (hu) |
SI (1) | SI3523283T1 (hu) |
TW (1) | TWI769182B (hu) |
UA (1) | UA124770C2 (hu) |
WO (1) | WO2018067860A1 (hu) |
ZA (1) | ZA201901744B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5042215B2 (ja) | 2005-05-26 | 2012-10-03 | ニューロン システムズ, インコーポレイテッド | 網膜疾患を処置するための組成物および方法 |
DK3359528T3 (en) * | 2015-10-07 | 2022-03-07 | Mitobridge Inc | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
PL3523283T3 (pl) | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
JP2021533154A (ja) * | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
JP7397491B2 (ja) * | 2018-10-23 | 2023-12-13 | 国立研究開発法人科学技術振興機構 | PPARδ活性化剤 |
CA3221429A1 (en) | 2021-06-02 | 2022-12-08 | Astellas Pharma Inc. | Methods of use of ppar agonist compounds and pharmaceutical compositions thereof |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
EP1671633A1 (en) * | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
KR100929069B1 (ko) | 2005-02-03 | 2009-11-30 | 아이알엠 엘엘씨 | Ppar 조절제로서의 화합물 및 조성물 |
CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2,4-二酮在制备ppar激动剂中的应用 |
US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
DK3359528T3 (en) * | 2015-10-07 | 2022-03-07 | Mitobridge Inc | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
KR102430906B1 (ko) * | 2016-04-13 | 2022-08-10 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
US20210283116A1 (en) | 2016-10-05 | 2021-09-16 | Mitobridge, Inc. | Methods of treating acute kidney injury |
PL3523283T3 (pl) | 2016-10-05 | 2021-12-13 | Mitobridge, Inc. | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
-
2017
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 MX MX2019003945A patent/MX2019003945A/es unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Application Discontinuation
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 BR BR112019006030A patent/BR112019006030A2/pt active Search and Examination
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en active Application Filing
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-20 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265730A (en) | Crystalline forms and salts of ppar agonist compounds | |
IL254351A0 (en) | An acid addition salt of a trk inhibitory compound | |
IL269626A (en) | Crystalline salt forms of BOC-D-ARG-DMT-LYS-(BOC)-PHE-NH2 | |
SI3380554T1 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
HK1244274A1 (zh) | C21h22ci2n4o2的晶型 | |
IL247143B (en) | A new use of agonistic compounds for the sigma-1 receptor | |
PT3560925T (pt) | Novo composto e sal farmaceuticamente aceitável deste | |
PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
IL260004A (en) | Crystalline forms of quinolone analogs and their salts | |
IL253479A0 (en) | Crystalline forms of efinconazole | |
PT3113773T (pt) | Formas cristalinas do grapiprant | |
IL274758A (en) | Crystalline forms of praquinostat | |
ZA201607107B (en) | Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound | |
IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
IL270937A (en) | Crystalline forms of saltalicib | |
GB201621771D0 (en) | New salts of compounds and uses thereof | |
HUP1600613A2 (en) | Crystalline forms of sacubitril hemicalcium salt | |
HK1244006A1 (zh) | Parp抑制劑的結晶形式 | |
GB201621528D0 (en) | Use of trpv1 agonist |